LPA₂ Alleviates Septic Acute Lung Injury via Protective Endothelial Barrier Function Through Activation of PLC-PKC-FAK

References

• Cheng Z, Abrams ST, Toh J, et al. The critical roles and mechanisms of immune cell death in sepsis. Front Immunol. 2020;11:1918. doi:10.3389/fimmu.2020.01918
   PubMed Web of Science ®Google Scholar
• Fukatsu M, Ohkawara H, Wang X, et al. The suppressive effects of Mer inhibition on inflammatory responses in the pathogenesis of LPS-induced ALI/ARDS. Sci Signal. 2022;15(724):eabd2533. doi:10.1126/scisignal.abd2533
   PubMed Web of Science ®Google Scholar
• Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. 2021;117(1):60–73. doi:10.1093/cvr/cvaa070
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Y, Feng Q, et al. Inhibition of the C3a receptor attenuates sepsis-induced acute lung injury by suppressing pyroptosis of the pulmonary vascular endothelial cells. Free Radic Biol Med. 2022;184:208–217. doi:10.1016/j.freeradbiomed.2022.02.032
   PubMed Web of Science ®Google Scholar
• Yang L, Liu S, Han S, et al. The HDL from septic-ARDS patients with composition changes exacerbates pulmonary endothelial dysfunction and acute lung injury induced by cecal ligation and puncture (CLP) in mice. Respir Res. 2020;21(1):293. doi:10.1186/s12931-020-01553-3
   PubMed Web of Science ®Google Scholar
• Abraham S, Yeo M, Montero-Balaguer M, et al. VE-Cadherin-mediated cell-cell interaction suppresses sprouting via signaling to MLC2 phosphorylation. Curr Biol. 2009;19(8):668–674. doi:10.1016/j.cub.2009.02.057
   PubMed Web of Science ®Google Scholar
• Chen D, Shen M, Wang H, et al. Sirt3 maintains microvascular endothelial adherens junction integrity to alleviate sepsis-induced lung inflammation by modulating the interaction of VE-cadherin and β-catenin. Oxid Med Cell Longev. 2021;2021:8978795. doi:10.1155/2021/8978795
   PubMed Web of Science ®Google Scholar
• Li Y, Chen H, Shu R, et al. Hydrogen treatment prevents lipopolysaccharide-induced pulmonary endothelial cell dysfunction through RhoA inhibition. Biochem Biophys Res Commun. 2020;522(2):499–505. doi:10.1016/j.bbrc.2019.11.101
   PubMed Web of Science ®Google Scholar
• Liu Y, Mu S, Li X, Liang Y, Wang L, Ma X. Unfractionated heparin alleviates sepsis-induced acute lung injury by protecting tight junctions. J Surg Res. 2019;238:175–185. doi:10.1016/j.jss.2019.01.020
   PubMed Web of Science ®Google Scholar
• Koval M. Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol. 2013;75(1):551–567. doi:10.1146/annurev-physiol-030212-183809
   PubMedGoogle Scholar
• Wang F, Liu S, Pei J, et al. LPA (3)-mediated lysophosphatidic acid signaling promotes postnatal heart regeneration in mice. Theranostics. 2020;10(24):10892–10907. eCollection 2020. doi:10.7150/thno.47913
   PubMed Web of Science ®Google Scholar
• Yin F, Watsky MA. LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance. Invest Ophthalmol Vis Sci. 2005;46(6):1927–1933. doi:10.1167/iovs.04-1256
   PubMed Web of Science ®Google Scholar
• Minnear F, Patil S, Bell D, Gainor JP, Morton CA. Platelet lipid(s) bound to albumin increases endothelial electrical resistance: mimicked by LPA. Am J Physiol Lung Cell Mol Physiol. 2001;281(6):L1337–L1344. doi:10.1152/ajplung.2001.281.6.L1337
   PubMed Web of Science ®Google Scholar
• Meeteren LA, Ruurs P, Stortelers C, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol. 2006;26(13):5015–5022. doi:10.1128/MCB.02419-05
   PubMed Web of Science ®Google Scholar
• Tanaka M, Okudaira S, Kishi S, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006;281(35):25822–25830. doi:10.1074/jbc.M605142200
   PubMed Web of Science ®Google Scholar
• Teo ST, Teo S, Yung YC, Herr DR, Chun J. Lysophosphatidic acid in vascular development and disease. IUBMB Life. 2009;61(8):791–799. doi:10.1002/iub.220
   PubMed Web of Science ®Google Scholar
• Pei J, Cai L, Wang F, et al. LPA2 contributes to vascular endothelium homeostasis and cardiac remodeling after myocardial infarction. Circ Res. 2022;131(5):388–403. doi:10.1161/CIRCRESAHA.122.321036
   PubMed Web of Science ®Google Scholar
• Kihara Y, Maceyka M, Spiegel S, et al. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575–3594. doi:10.1111/bph.12678
   PubMed Web of Science ®Google Scholar
• Patil R, Szabó E, Fells JI, et al. Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist. Chem Biol. 2015;22(2):206–216. doi:10.1016/j.chembiol.2014.12.009
   PubMedGoogle Scholar
• He D, Su Y, Usatyuk PV, et al. Lysophosphatidic acid enhances pulmonary epithelial barrier integrity and protects endotoxin-induced epithelial barrier disruption and lung injury. J Biol Chem. 2009;284(36):24123–24132. doi:10.1074/jbc.M109.007393
   PubMed Web of Science ®Google Scholar
• Jiang J, Huang K, Xu S, Garcia JG, Wang C, Cai H. Targeting NOX4 alleviates sepsis-induced acute lung injury via attenuation of redox-sensitive activation of CaMKII/ERK1/2/MLCK and endothelial cell barrier dysfunction. Redox Biol. 2020;36:101638. doi:10.1016/j.redox.2020.101638
   PubMed Web of Science ®Google Scholar
• Yeomyeong K, Sungwoon L, Haiying Z, et al. CLEC14A deficiency exacerbates neuronal loss by increasing blood-brain barrier permeability and inflammation. J Neuroinflammation. 2020;17(1):48. doi:10.1186/s12974-020-1727-6
   PubMed Web of Science ®Google Scholar
• Im K, Mareninov S, Diaz MF, Yong WH. An introduction to performing immunofluorescence staining. Methods Mol Biol. 2019;1897:299–311. doi:10.1007/978-1-4939-8935-5_26
   PubMedGoogle Scholar
• Yang R, Yang H, Wei J, et al. Mechanisms underlying the effects of lianhua qingwen on sepsis-induced acute lung injury: a network pharmacology approach. Front Pharmacol. 2021;12:717652. eCollection 2021. doi:10.3389/fphar.2021.717652
   PubMedGoogle Scholar
• Chrzanowska-Wodnicka M, Kraus AE, Gale D, et al. Defective angiogenesis, endothelial migration, proliferation, and MAPK signaling in Rap1b-deficient mice. Blood. 2008;111(5):2647–2656. doi:10.1182/blood-2007-08-109710
   PubMed Web of Science ®Google Scholar
• Kuck JL, Bastarache JA, Shaver CM, Fessel JP, Dikalov SI, May JM. Ascorbic acid attenuates endothelial permeability triggered by cell-free hemoglobin. Biochem Biophys Res Commun. 2018;495(1):433–437. doi:10.1016/j.bbrc.2017.11.058
   PubMed Web of Science ®Google Scholar
• Li Z, Yin M, Zhang H, et al. BMX represses thrombin-PAR1-mediated endothelial permeability and vascular leakage during early sepsis. Circ Res. 2020;126(4):471–485. doi:10.1161/CIRCRESAHA.119.315769
   PubMed Web of Science ®Google Scholar
• Chen X, Yang X, Wang ND, et al. Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction. Scand J Clin Lab Invest. 2003;63(7–8):497–503. doi:10.1080/00365510310003265
   PubMed Web of Science ®Google Scholar
• Panchatcharam M, Miriyala S, Yang F, et al. Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res. 2008;103(6):662–670. doi:10.1161/CIRCRESAHA.108.180778
   PubMed Web of Science ®Google Scholar
• Dohi T, Miyauchi K, Ohkawa R, et al. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis. 2013;229(1):192–197. doi:10.1016/j.atherosclerosis.2013.03.038
   PubMed Web of Science ®Google Scholar
• Kurano M, Kano K, Dohi T, et al. Different origins of lysophospholipid mediators between coronary and peripheral arteries in acute coronary syndrome. J Lipid Res. 2017;58(2):433–442. doi:10.1194/jlr.P071803
   PubMed Web of Science ®Google Scholar
• Sumitomo A, Siriwach R, Thumkeo D, et al. LPA induces keratinocyte differentiation and promotes skin barrier function through the LPAR1/LPAR5-RHO-ROCK-SRF Axis. J Invest Dermatol. 2019;139(5):1010–1022. doi:10.1016/j.jid.2018.10.034
   PubMed Web of Science ®Google Scholar
• Alexander JS, Patton WF, Christman BW, Cuiper LL, Haselton FR. Platelet-derived lysophosphatidic acid decreases endothelial permeability in vitro. Am J Physiol. 1998;274(1):H115–H122. doi:10.1152/ajpheart.1998.274.1
   PubMedGoogle Scholar
• Van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol. 2000;20(12):E127–E133. doi:10.1161/01.atv.20.12.e127
   PubMed Web of Science ®Google Scholar
• Schulze C, Smales C, Rubin LL, Staddon JM. Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem. 1997;68(3):991–1000. doi:10.1046/j.1471-4159.1997.68030991.x
   PubMed Web of Science ®Google Scholar
• Cai J, Wei J, Li S, Suber T, Zhao J. AM966, an antagonist of lysophosphatidic acid receptor 1, increases lung microvascular endothelial permeability through activation of rho signaling pathway and phosphorylation of VE-Cadherin. Mediators Inflamm. 2017;2017:6893560. doi:10.1155/2017/6893560
   PubMed Web of Science ®Google Scholar
• Inoue A, Arima N, Ishiguro J, et al. LPA-producing enzyme PA-PLA 1 α regulates hair follicle development by modulating EGFR signalling. EMBO J. 2011;30(20):4248–4260. doi:10.1038/emboj.2011.296
   PubMed Web of Science ®Google Scholar
• Nitzsche A, Poittevin M, Benarab A, et al. Endothelial S1P (1) signaling counteracts infarct expansion in ischemic stroke. Circ Res. 2021;128(3):363–382. doi:10.1161/CIRCRESAHA.120.316711
   PubMed Web of Science ®Google Scholar
• Chun J, Kihara Y, Jonnalagadda D, Blaho VA. Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders. Annu Rev Pharmacol Toxicol. 2019;59(1):149–170. doi:10.1146/annurev-pharmtox-010818-021358
   PubMedGoogle Scholar
• Cohan SL, Benedict RH, Cree BA, Deluca J, Hua LH, Chun J. The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis. CNS Drugs. 2022;36(7):703–719. doi:10.1007/s40263-022-00927-z
   PubMed Web of Science ®Google Scholar
• Zhang N, Tang S, Zhang J, Pei B, Pang T, Sun G. The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates LPS-induced acute lung injury by maintenance of pulmonary microvascular barrier via activating the Epac1/AKT pathway. Biomed Pharmacother. 2022;155:113704. doi:10.1016/j.biopha.2022.113704
   PubMed Web of Science ®Google Scholar